. Eli Lilly and Company (NYSE: LLY) today announced the outcome of the U. Eli Lilly. Trial participants taking the highest dose of tirzepatide (00 mg) achieved an A0C reduction of 0. Trial participants taking the highest dose of tirzepatide (00 mg) achieved an A0C 